Acular 0.5% w/v Eye Drops, solution Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

acular 0.5% w/v eye drops, solution

imed healthcare ltd. - ketorolac trometamol - eye drops, solution - antiinflammatory agents, non-steroids; ketorolac

Acular 0,4 % Namibia - Inggeris - Namibia Medicines Regulatory Council

acular 0,4 %

allergan pharmaceuticals (pty) ltd - ketorolac tromethamine - ophthalmic solution - acular 0,4 % ophthalmic solution contains ketorolac tromethamine 4 mg / ml

Yesafili Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).

Acular New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

acular

abbvie limited - ketorolac trometamol 5 mg/ml;  ;   - eye drops, solution - 0.5% w/v - active: ketorolac trometamol 5 mg/ml     excipient: benzalkonium chloride disodium edetate dihydrate hydrochloric acid macrogols purified water sodium chloride sodium hydroxide

ACULAR SOLUTION Kanada - Inggeris - Health Canada

acular solution

abbvie corporation - ketorolac tromethamine - solution - 0.5% - ketorolac tromethamine 0.5% - nonsteroidal anti-inflammatory agents

ACULAR LS SOLUTION Kanada - Inggeris - Health Canada

acular ls solution

abbvie corporation - ketorolac tromethamine - solution - 0.4% - ketorolac tromethamine 0.4% - nonsteroidal anti-inflammatory agents

ACULAR 0,4% (ophthalmic solution) Afrika Selatan - Inggeris - South African Health Products Regulatory Authority (SAHPRA)

acular 0,4% (ophthalmic solution)

allergan -

Eylea Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

eylea

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Byooviz Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

Ximluci Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)